{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T04:24:58Z","timestamp":1692851098755},"reference-count":28,"publisher":"Georg Thieme Verlag KG","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Was ist neu?<\/jats:title><jats:p>\n            Einteilung und Risikostratifizierung Zunehmende Bedeutung gewinnt die prim\u00e4re Durchf\u00fchrung einer Risikostratifizierung, die f\u00fcr die weiteren diagnostischen und therapeutischen Schritte ma\u00dfgeblich ist.<\/jats:p><jats:p>\n            Diagnostik Zur Sicherung der klinischen Diagnose stehen verschiedene non-invasive Verfahren zur Verf\u00fcgung. Eine histologische Diagnosesicherung wird in unklaren F\u00e4llen empfohlen. Bei schlecht verschieblichen L\u00e4sionen sollte eine pr\u00e4operative Schnittbildgebung des Tumorareals erfolgen zum Ausschluss einer oss\u00e4ren Infiltration.<\/jats:p><jats:p>\n            Therapie Goldstandard in der Behandlung bleibt weiterhin das operative Vorgehen, welches m\u00f6glichst mittels mikrografisch kontrollierter Chirurgie erfolgen sollte. Daneben existieren weitere Therapieverfahren wie die Radiotherapie oder eine Reihe an topischen Therapieoptionen (photodynamische Therapie, Kryotherapie oder Applikation von 5-Fluoruracil bzw. Imiquimod), die in bestimmten F\u00e4llen zur Anwendung kommen k\u00f6nnen. Auch f\u00fcr fortgeschrittene oder metastasierte Basalzellkarzinome stehen mit den Hedgehog-Inhibitoren wirksame Medikamente zur Verf\u00fcgung, f\u00fcr die inzwischen eine mehrj\u00e4hrige Anwendungserfahrung hinsichtlich Wirksamkeit und Umgang mit unerw\u00fcnschten Ereignissen vorliegt. Mit dem PD-1-Inhibitor Cemiplimab steht seit Juni 2021 eine weitere therapeutische Option f\u00fcr nicht operable oder metastasierte Tumoren bereit.<\/jats:p><jats:p>\n            Pr\u00e4vention und Nachsorge Wichtigste Ma\u00dfnahme ist ein konsequenter textiler oder chemischer UV-Schutz bei bereits betroffenen Personen. Dar\u00fcber hinaus k\u00f6nnen Nicotinamid und Celecoxib oral zur Pr\u00e4vention eingesetzt werden. Zur Nachsorge werden von der aktuellen S2k-Leitlinie regelm\u00e4\u00dfigen Selbstkontrollen und standardisierte \u00e4rztliche Kontrolluntersuchungen empfohlen.<\/jats:p>","DOI":"10.1055\/a-1958-2603","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T22:30:52Z","timestamp":1692829852000},"page":"1081-1087","source":"Crossref","is-referenced-by-count":0,"title":["Aktuelles Management des Basalzellkarzinoms"],"prefix":"10.1055","volume":"148","author":[{"given":"Manuel","family":"Krieter","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinik f\u00fcr Dermatologie, Paracelsus Medizinische Privatuniversit\u00e4t N\u00fcrnberg, N\u00fcrnberg, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erwin","family":"Schultz","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinik f\u00fcr Dermatologie, Paracelsus Medizinische Privatuniversit\u00e4t N\u00fcrnberg, N\u00fcrnberg, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2023,8,23]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1056\/NEJMra044151","article-title":"Basal-cell carcinoma","volume":"353","author":"AI Rubin","year":"2005","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/j.1365-2133.2012.10830.x","article-title":"A systematic review of worldwide incidence of nonmelanoma skin cancer","volume":"166","author":"A Lomas","year":"2012","journal-title":"Br J Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1111\/bjd.14352","article-title":"GEKID Cancer Survival Working Group. Survival with nonmelanoma skin cancer in Germany","volume":"174","author":"N Eisemann","year":"2016","journal-title":"Br J Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/ijc.2910600411","article-title":"Does intermittent sun exposure cause basal cell carcinoma? A case-control study in Western Australia","volume":"60","author":"A Kricker","year":"1995","journal-title":"Int J Cancer"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1111\/php.12807","article-title":"Early Life UV and Risk of Basal and Squamous Cell Carcinoma in New South Wales, Australia","volume":"93","author":"A Kricker","year":"2017","journal-title":"Photochem Photobiol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/ddg.13733_g","article-title":"S2k-Leitlinie Basalzellkarzinom der Haut \u2013 Teil 1: Epidemiologie, Genetik und Diagnostik","volume":"17","author":"BM Lang","year":"2019","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/bjd.14153","article-title":"Risk of basal cell carcinoma in Swedish organ transplant recipients: a population-based study","volume":"174","author":"B Krynitz","year":"2016","journal-title":"Br J Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/ijd.14065","article-title":"Bazex-Dupr\u00e9-Christol syndrome: review of clinical and molecular aspects","volume":"57","author":"MM Al Sabbagh","year":"2018","journal-title":"Int J Dermatol"},{"key":"ref9","first-page":"13","volume-title":"Basal cell carcinoma","author":"S Kossard","year":"2006"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2016.0065","volume-title":"Basal Cell Skin Cancer, Version 1. 2016, NCCN Clinical Practice Guidelines in Oncology","author":"CK Bichakjian","year":"2016"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ejca.2019.06.003","article-title":"Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines","volume":"118","author":"K Peris","year":"2019","journal-title":"Eur J Cancer"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/bjd.14499","article-title":"Preoperative prediction of histopathological outcome in basal cell carcinoma: flat surface and multiple small erosions predict superficial basal cell carcinoma in lighter skin types","volume":"175","author":"I Ahnlide","year":"2016","journal-title":"Br J Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.jaad.2015.12.038","article-title":"Standardization of terminology in dermoscopy\/dermatoscopy: results of the third consensus conference of the International Society of Dermoscopy","volume":"74","author":"H Kittler","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/bjd.13853","article-title":"The sensitivity and specificity of optical coherence tomography for the assisted diagnosis of nonpigmented basal cell carcnoma: an observational study","volume":"173","author":"M Ulrich","year":"2015","journal-title":"Br J Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"CD013189","DOI":"10.1002\/14651858.CD013189","article-title":"Cochrane skin cancer diagnostic test accuracy group. Optical coherence tomography for diagnosing skin cancer in adults","volume":"12","author":"L Ferrante di Ruffano","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/ced.13055","article-title":"Diagnostic accuracy of reflectance confocal microscopy using VivaScope for detecting and monitoring skin lesions: a systematic review","volume":"42","author":"SJ Edwards","year":"2017","journal-title":"Clin Exp Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/j.1600-0846.2012.00643.x","article-title":"Diagnosis of BCC by multiphoton laser tomography","volume":"19","author":"S Seidenari","year":"2013","journal-title":"Skin Res Technol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.jid.2017.09.033","article-title":"Five-Year Results of a Randomized Controlled Trial Comparing Effectiveness of Photodynamic Therapy, Topical Imiquimod, and Topical 5-Fluorouracil in Patients with Superficial Basal Cell Carcinoma","volume":"138","author":"MHE Jansen","year":"2018","journal-title":"J Invest Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1111\/bjd.13253","article-title":"Utility of radiotherapy for treatment of basal cell carcinoma: a review","volume":"171","author":"M Cho","year":"2014","journal-title":"Br J Dermatol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/S1470-2045(15)70100-2","article-title":"Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, doubleblind phase 2 trial","volume":"16","author":"MR Migden","year":"2015","journal-title":"Lancet Oncol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.ejca.2017.08.022","article-title":"Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, openlabel trial","volume":"86","author":"N Basset-S\u00e9guin","year":"2017","journal-title":"Eur J Cancer"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1634\/theoncologist.2016-0186","article-title":"Characterization and management of hedgehog pathway inhibitor-related adverse events in patients with advanced basal cell carcinoma","volume":"21","author":"ME Lacouture","year":"2016","journal-title":"Oncologist"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"100844","DOI":"10.1016\/j.eclinm.2021.100844.","article-title":"Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study): Neoadjuvant Vismodegib in Locally Advanced Basal Cell Carcinoma","volume":"35","author":"N Bertrand","year":"2021","journal-title":"EClinicalMedicine"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/S1470-2045(21)00126-1","article-title":"Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial","volume":"22","author":"A Stratigos","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1056\/NEJMoa1506197","article-title":"A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention","volume":"373","author":"AC Chen","year":"2015","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jaad.2015.08.034","article-title":"Can oral nonsteroidal antiinflammatory drugs play a role in the prevention of basal cell carcinoma? A systematic review and metaanalysis","volume":"74","author":"C Muranushi","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1016\/j.ejca.2013.03.010","article-title":"Risk of subsequent cutaneous malignancy in patients with prior keratinocyte carcinoma: a systematic review and meta-analysis","volume":"49","author":"SC Flohil","year":"2013","journal-title":"Eur J Cancer"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/ddg.13755_g","article-title":"S2k-Leitlinie Basalzellkarzinom der Haut \u2013 Teil 2: Therapie, Pr\u00e4vention und Nachsorge","volume":"17","author":"BM Lang","year":"2019","journal-title":"J Dtsch Dermatol Ges"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1958-2603.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T22:31:07Z","timestamp":1692829867000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1958-2603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,23]]},"references-count":28,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2023,8,23]]},"published-print":{"date-parts":[[2023,9]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1958-2603","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,23]]}}}